Systematic (IUPAC) name
5-[2-(methylamino)ethyl]-2-[(2-methylpropanoyl)oxy]phenyl 2-methylpropanoate
Clinical data
Legal status
CAS number  YesY
ATC code C01 S01
ChemSpider  N
Chemical data
Formula C17H25NO4 
Mol. mass 307.385 g/mol

Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine, used in ophthalmology.[1] It induces mydriasis.[2] It also has been investigated for use in the treatment of congestive heart failure.[3]

It acts on D1[4][5] and α receptors as an agonist.[6]

Ibopamine was first prepared by Casagrande and co-workers.[7]

See also


  1. ^ Magacho L, Costa ML, Dessimoni A, de Avila MP (2006). "Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability". Arq Bras Oftalmol 69 (5): 695–9.  
  2. ^ Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L (June 2001). "Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure". J Ocul Pharmacol Ther 17 (3): 215–23.  
  3. ^ van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, et al. (November 1993). "Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)". J. Am. Coll. Cardiol. 22 (6): 1564–73.  
  4. ^ Metra M, Missale C, Spano PF, Cas LD (May 1995). "Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine". J. Cardiovasc. Pharmacol. 25 (5): 732–40.  
  5. ^ Lieverse AG, Girbes AR, Van Veldhuisen DJ, et al. (July 1995). "The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure". Eur. Heart J. 16 (7): 937–42.  
  6. ^ "IngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re...". 
  7. ^ C. Casagrande, F. Santangelo, C. Saini, F. Doggi, F. Gerli and O. Cerri (1986). "Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites." Arzneimittelforschung 36 291-303.